Evidence map›Paper›PMID 39233619›Full record

ArticleESC heart failure2025

Integrin beta-like 1 is regulated by DNA methylation and increased in heart failure patients.

Lauren Kerrigan, Kevin Edgar, Adam Russell-Hallinan, Oisin Cappa, Nadezhda Glezeva, Carlos Galan-Arriola, Eduardo Oliver, Borja Ibanez, John Baugh, Patrick Collier and 6 more

Abstract read
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Methylations in dilated cardiomyopathy and heart failure.Frontiers in cardiovascular medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lauren KerriganWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0001-9185-4666
Kevin EdgarWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Adam Russell-HallinanWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Oisin CappaWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Nadezhda GlezevaUCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.
Carlos Galan-ArriolaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Eduardo OliverCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Borja IbanezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
John BaughUCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.
Patrick CollierDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Mark LedwidgeUCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.
Ken McDonaldUCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.
David SimpsonWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Sudipto DasRoyal College of Surgeons, Dublin, Ireland.
David J GrieveWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Chris J WatsonWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.

Funding

British Heart Foundation PG/18/21/33599British Heart Foundation PG/20/10424Heart Research UK RG2662
6 · The paper itself

Abstract

aimsDynamic alterations in cardiac DNA methylation have been implicated in the development of heart failure (HF) with evidence of ischaemic heart disease (IHD); however, there is limited research into cell specific, DNA methylation sensitive genes that are affected by dysregulated DNA methylation patterns. In this study, we aimed to identify DNA methylation sensitive genes in the ischaemic heart and elucidate their role in cardiac fibrosis.

methodsA multi-omics integrative analysis was carried out on RNA sequencing and methylation sequencing on HF with IHD (n = 9) versus non-failing (n = 9) left ventricular tissue, which identified Integrin beta-like 1 (ITGBL1) as a gene of interest. Expression of Itgbl1 was assessed in three animal models of HF; an ischaemia-reperfusion pig model, a myocardial infarction mouse model and an angiotensin-II infused mouse model. Single nuclei RNA sequencing was carried out on heart tissue from angiotensin-II infused mice to establish the expression profile of Itgbl1 across cardiac cell populations. Subsequent in vitro analyses were conducted to elucidate a role for ITGBL1 in human cardiac fibroblasts. DNA pyrosequencing was applied to assess ITGBL1 CpG methylation status in genomic DNA from human cardiac tissue and stimulated cardiac fibroblasts.

resultsITGBL1 was >2-fold up-regulated (FDR adj P = 0.03) and >10-fold hypomethylated (FDR adj P = 0.01) in human HF with IHD left ventricular tissue compared with non-failing controls. Expression of Itgbl1 was up-regulated in three isolated animal models of HF and showed conserved correlation between increased Itgbl1 and diastolic dysfunction. Single nuclei RNA sequencing highlighted that Itgbl1 is primarily expressed in cardiac fibroblasts, while functional studies elucidated a role for ITGBL1 in cardiac fibroblast migration, evident in 50% reduced 24 h fibroblast wound closure occurring subsequent to siRNA-targeted ITGBL1 knockdown. Lastly, evidence provided from DNA pyrosequencing supports the theory that differential expression of ITGBL1 is caused by DNA hypomethylation.

conclusionsITGBL1 is a gene that is mainly expressed in fibroblasts, plays an important role in cardiac fibroblast migration, and whose expression is significantly increased in the failing heart. The mechanism by which increased ITGBL1 occurs is through DNA hypomethylation.

Indexed as

DNA MethylationGene Expression RegulationHeart FailureIntegrin beta1AnimalsCells, CulturedDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedSwineIntegrin beta1DNA methylationEpigeneticsHeart failureIschaemic cardiomyopathySingle nuclei RNA sequencing: cardiac fibroblasts

Identifiers

PMID39233619
PMCPMC11769624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.